Wellington Partners backs €34m Series D round for kidney cancer vaccine maker Immatics


biomed_lrgEuropean venture capital firm Wellington Partners was among backers of a €34m Series D financing round for German anti-cancer vaccine maker Immatics Biotechnologies.

Funds advised by MIG also took part in the funding round, as did Dievini Hopp Biotech Holding and AT Impf.

Immatics, which is developing a drug designed to combat kidney cancer, will receive the first €12m tranche of funding immediately to conclude development of its lead vaccine.

Earlier this month Netherlands-based biopharmaceutical company Merus closed a €31m extension to its Series B financing round, bringing the total round to €47.6m.

Merus said it would use the new funds to broaden its portfolio of pre-clinical programs for the treatment of cancer patients and bring its lead programs into phase I clinical testing.

A day earlier founding Loxo Oncology investor Aisling Capital revealed it had upped its commitment to the cancer treatment biopharma business by taking part in a $33m Series A financing round.

OrbiMed Advisors and an undisclosed investor also took part in the round, which Loxo said would be used to advance its lead product candidate through clinical proof of concept as well as launching a second programme.

Copyright © 2013 AltAssets